Provided By

This educational activity is jointly provided by

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 28, 2020
Expires: August 27, 2021
30 minutes to complete

Target Audience

This activity is intended for urologists, primary care physicians, geriatricians and obstetricians-gynecologists.

Learning Objectives

Upon completion of this activity in this initiative, participants should be able to:

  • Identify factors which contribute to high discontinuation rates for antimuscarinic therapy.
  • Describe strategies to optimize OAB treatment efficacy while minimizing treatment related intolerances.
  • Summarize the implications of OAB treatment in the elderly population.

Activity Description

This Expert Exchange webcast is designed to improve clinicians’ awareness of the latest evidence-based guidelines and recommendations for treating OAB in special populations.

Statement of Educational Need

Limited treatment options and an overall rate of underdiagnosis and undertreatment highlight the necessity of ongoing education to help providers appropriately query patients about symptom occurrence and diagnose OAB, properly educate on non-pharmacological options, and actively treat OAB. Health care providers should be aware of therapeutic nuances between medication options to best select therapy and evaluate strengths and weaknesses of selected therapies.


David Staskin, MD
Associate Professor of Urology
Tufts University School of Medicine
Director, Center for Male and Female Pelvic Health
St. Elizabeth’s Medical Center
Boston, MA

Scott A. MacDiarmid, MD, FRCPSC
Associate Professor of Urology
University of North Carolina at Chapel Hill
Director, Alliance Urology Continence Center
Greensboro, NC

Adrian Wagg, MB, BS, FRCP (Lond), FRCP (Edin), FHEA (MD)
Professor of Healthy Ageing
University of Alberta
Professor of Continence Sciences
University of Gothenburg (Sweden)
Edmonton, Alberta, Canada

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals, and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

David R. Staskin, MD
Receives research support/CME Faculty/Peer Reviewer/Speakers Bureau/Advisor/Consultant: Astellas Pharma.
Receives research support/Consultant: Urovant Sciences.

Scott A. MacDiarmid, MD, FRCPSC
Consultant/Speakers Bureau: Astellas Pharma, Allergan, and Medtronic.
Consultant: Labont and Urovant Sciences.

Adrian Wagg, MB, BS, FRCP (Lond), FRCP (Edin), FHEA (MD)
Consultant/receives research support: Essity Health & Hygiene AB; Pfizer Corporation.
Speakers bureau/advisor:
Astellas Pharma and Pfizer Corporation.
Employment (spouse): Pfizer Corporation.

The planners, managers and reviewers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. The following AXIS and Novus planners, managers, and reviewers:  Steven Scrivner, MPA, CHCP; Megan E. Adelman, PharmD; Ronald Viggiani, MD; and Dee Morgillo, MEd., MT(ASCP), CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and NOVUS Medical Education. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation for Physicians

AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Astellas Pharma US.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.